TRPV1 and Anxiety: Preclinical studies in adult male mice demonstrate that the TRPV1 antagonist capsazepine reduces corneal sensitivity to noxious stimuli, alleviates pain, and diminishes DED-related anxiety, highlighting its therapeutic potential [142].